A 28.8-day half-life is the number that matters most in the RESP-X Phase IIa readout — not because it is impressive on its own, but because it is precisely the pharmacokinetic lever that makes quarterly dosing biologically plausible in a chronic respiratory disease where patient burden is already punishing. Infex Therapeutics enrolled NCFB patients colonised with Pseudomonas aeruginosa across two dose cohorts, 6 mg/kg and 10 mg/kg, at a single UK clinical research facility. The 10 mg/kg arm achieved serum coverage above the PK/PD target sufficient to span three-month intervals, and bronchoscopy confirmed antibody presence in epithelial lining fluid at 48 hours post-dose — the anatomical site where it actually needs to work.
The mechanism here is genuinely distinct from anything currently approved or late-stage in NCFB. RESP-X is an anti-virulence monoclonal targeting PcrV, the tip protein of Pseudomonas‘s Type III Secretion System. It does not kill the bacterium. It disarms it — blocking exotoxin delivery and restoring macrophage-mediated clearance. Every Pa isolate collected from patient sputum throughout the study encoded PcrV, and every target sequence bound RESP-X, which means the drug’s coverage assumption held across real-world clinical isolates, not just lab strains. No anti-drug antibodies appeared at any timepoint, which removes a meaningful development risk for a chronically dosed biologic.
The efficacy signal is preliminary but directionally coherent. Pa-positive patients experienced fewer exacerbations from day 1 through day 180 compared with the preceding 12 months, with a p-value of 0.08. That does not cross conventional significance thresholds, and this was an exploratory endpoint in a safety-primary Phase IIa study that ran at a single site — small n, no power calculation for efficacy. The honest read is that the signal justifies a powered Phase IIb/III, not that it confirms clinical benefit. Safety was clean: no severe treatment-emergent adverse events, no infusion reactions, no withdrawals.
The Phase III design — specifically how Infex and regulators define the primary efficacy endpoint, exacerbation rate reduction or time-to-first-exacerbation — will determine whether a p=0.08 exploratory hint translates into a registration-quality effect size. That regulatory alignment discussion is the single development milestone worth tracking now.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
